Monitor the company's ability to close the full offering given the best-efforts structure and no minimum. Watch for Nasdaq compliance updates — the company's stock is below $1.00 and a reverse split authorization is pending. The massive warrant overhang (43.6M shares underlying Series D Warrants) will pressure the stock post-offering.
Executive Summary
Sunshine Biopharma priced a best-efforts offering of up to 10,509,082 Common Units at $0.55/unit, each consisting of one share of common stock and two Series D Warrants, for gross proceeds of approximately $6.0 million. The offering price represents a 62% premium to the $0.34 last sale price on October 9, 2026, and the company expects net proceeds of ~$5.2 million for general corporate purposes. The massive dilution (144% of pre-offering shares outstanding) and the company's ongoing Nasdaq bid-price deficiency risk make this a deeply bearish event.
Key Financial Metrics
Key Facts
- Offering of up to 10,509,082 Common Units at $0.55/unit, plus up to 400,000 Pre-Funded Units at $0.54999/unit.
- Gross proceeds of approximately $6.0 million; net proceeds estimated at ~$5.2 million after fees and expenses.
- Offering price is a 62% premium to the $0.34 last sale price on October 9, 2026.
- Common stock outstanding will increase from 4,310,301 to 15,219,383 shares — dilution of approximately 253% of pre-offering shares.
- Series D Warrants have an initial exercise price of $0.66 (120% of offering price) and a five-year term.
- Placement agent: Aegis Capital Corp.; 7% cash fee plus 1% non-accountable expense allowance.
- Executive officers and directors subject to a 90-day lock-up; company subject to a 90-day standstill.
- Company faces Nasdaq bid-price deficiency risk (stock trading below $1.00) and has a reverse stock split authorization effective October 19, 2026.
Financial Impact
Gross proceeds of $6.0 million; net proceeds ~$5.2 million. Dilution of 253% of pre-offering shares outstanding.
Risk Factors
- Extreme dilution: 253% increase in share count from the offering alone.
- Nasdaq delisting risk: stock trades well below $1.00 bid price requirement.
- Best-efforts offering with no minimum — may not raise full $6.0 million.
- Massive warrant overhang: up to 43.6M shares underlying Series D Warrants at $0.66 exercise price.
- Management has broad discretion over use of proceeds — no specific allocation.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001683168-26-007757 |
| Document: 0001683168-26-007757-index-headers.html | 0001683168-26-007757 |
| Document: 0001683168-26-007757-index.html | 0001683168-26-007757 |
| Document: 0001683168-26-007757.txt | 0001683168-26-007757 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | SC 13G | $0.2430 $0.2154 | ▼ −11.36% | ▼ −11.81% | $2.96 (+1118.11%) |
Oct 13, 2026 13d ago | SC 13G | $0.2430 $0.2154 | ▼ −11.36% | ▼ −11.81% | $2.96 (+1118.11%) |
Oct 9, 2026 17d ago | 8-K | $0.3020 $0.2418 | ▲ +19.93% | ▲ +18.44% | $2.96 (−880.13%) |
Oct 9, 2026 17d ago | 424B4 | $0.3020 $0.2418 | ▲ +19.93% | ▲ +18.44% | $2.96 (−880.13%) |
Oct 8, 2026 19d ago | EFFECT | $0.4300 $0.2300 | ▲ +46.51% | ▲ +46.24% | $2.96 (−588.37%) |
Oct 5, 2026 21d ago | SC 13G/A | $0.3979 $0.2363 | ▲ +40.61% | ▲ +40.47% | $2.96 (−643.91%) |
Oct 2, 2026 24d ago | S-1 | $0.4201 $0.3020 | ▲ +28.11% | ▲ +28.53% | $2.96 (−604.59%) |
Sep 9, 2026 6w ago | EFFECT | $1.12 $1.04 | ▲ +7.59% | ▲ +7.26% | $2.96 (−164.29%) |
Aug 28, 2026 8w ago | 8-K | $1.12 $1.15 | ▲ +2.68% | ▲ +2.82% | $2.96 (+164.29%) |
Aug 3, 2026 12w ago | 8-K | $23.40 $24.40 | ▲ +4.27% | ▲ +2.25% | $2.96 (−87.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers